Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran.
Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Cell Signal. 2024 Oct;122:111335. doi: 10.1016/j.cellsig.2024.111335. Epub 2024 Aug 6.
Sodium glucose cotransporter 2 inhibitors (SGLT2is) are a newly developed class of anti-diabetics which exert potent hypoglycemic effects in the diabetic milieu. However, the evidence suggests that they also have extra-glycemic effects. The renin-angiotensin-aldosterone system (RAAS) is a hormonal system widely distributed in the body that is important for water and electrolyte homeostasis as well as renal and cardiovascular function. Therefore, modulating RAAS activity is a main goal in patients, notably diabetic patients, which are at higher risk of complications involving these organ systems. Some studies have suggested that SGLT2is have modulatory effects on RAAS activity in addition to their hypoglycemic effects and, thus, these drugs can be considered as promising therapeutic agents for renal and cardiovascular disorders. However, the exact molecular interactions between SGLT2 inhibition and RAAS activity are not clearly understood. Therefore, in the current study we surveyed the literature for possible molecular mechanisms by which SGLT2is modulate RAAS activity.
钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2is）是一类新型的抗糖尿病药物，在糖尿病环境中具有强大的降血糖作用。然而，有证据表明它们也具有血糖外的作用。肾素-血管紧张素-醛固酮系统（RAAS）是一种广泛分布于体内的激素系统，对水和电解质平衡以及肾脏和心血管功能非常重要。因此，调节 RAAS 活性是患者（尤其是糖尿病患者）的主要目标，因为这些患者发生涉及这些器官系统的并发症的风险更高。一些研究表明，SGLT2is 除了具有降血糖作用外，还对 RAAS 活性具有调节作用，因此这些药物可以被视为治疗肾脏和心血管疾病的有前途的治疗剂。然而，SGLT2 抑制与 RAAS 活性之间的确切分子相互作用尚不清楚。因此，在本研究中，我们调查了文献中可能的分子机制，即 SGLT2is 如何调节 RAAS 活性。
